Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HEXA | P06865 | 1/20 | 0.35 |
| ▸ | HEXB | P07686 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395287 | 0.90 | HRH3 (0.44) | HRH3HRH4KCNH2PTPN11HEXA | |
| SCHEMBL4399752 | 0.87 | HRH4 (0.46) | HRH3HRH4KCNH2HRH2HRH1 | |
| SCHEMBL4402295 | 0.83 | DHFR (0.54) | HRH3HRH4PTPN11HEXAHEXB | |
| SCHEMBL4397056 | 0.81 | HRH4 (0.53) | HRH3HRH4KCNH2 | |
| SCHEMBL4398078 | 0.81 | HRH4 (0.53) | HRH3HRH4KCNH2 | |
| SCHEMBL4393790 | 0.79 | HRH4 (0.44) | HRH3HRH4KCNH2HRH2HRH1 | |
| SCHEMBL4398527 | 0.78 | HRH4 (0.43) | HRH3HRH4KCNH2PTPN11HRH2 | |
| SCHEMBL4401146 | 0.76 | HRH4 (0.42) | HRH3HRH4KCNH2HRH2HRH1 | |
| SCHEMBL4401322 | 0.76 | HRH4 (0.56) | HRH3HRH4KCNH2 | |
| SCHEMBL4390452 | 0.76 | RPS6KB1 (0.42) | HRH3HRH4PTPN11RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | HRH3 3/4885HRH4 1/4885KCNH2 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.